Kidney International Reports (Sep 2017)

Natural History and Genotype–Phenotype Correlation in Female X-Linked Alport Syndrome

  • Tomohiko Yamamura,
  • Kandai Nozu,
  • Xue Jun Fu,
  • Yoshimi Nozu,
  • Ming Juan Ye,
  • Akemi Shono,
  • Satoko Yamanouchi,
  • Shogo Minamikawa,
  • Naoya Morisada,
  • Koichi Nakanishi,
  • Yuko Shima,
  • Norishige Yoshikawa,
  • Takeshi Ninchoji,
  • Ichiro Morioka,
  • Hiroshi Kaito,
  • Kazumoto Iijima

DOI
https://doi.org/10.1016/j.ekir.2017.04.011
Journal volume & issue
Vol. 2, no. 5
pp. 850 – 855

Abstract

Read online

X-linked Alport syndrome (XLAS) is a hereditary disease characterized by progressive nephritis, hearing loss, and ocular abnormalities. Affected male patients usually progress to end-stage renal disease in early or middle adulthood, and disease severity is strongly correlated with genotype. However, the clinical course in female patients has rarely been reported. Methods: We conducted a retrospective analysis of females with genetically proven XLAS (n = 275) and their affected female family members (n = 61) from 179 Japanese families. Patients suspected to have Alport syndrome from pathologic findings or a family history who were referred from anywhere in Japan for genetic diagnosis between 2006–2015 were included in this study. Clinical and laboratory data were collected from medical records at the time of registration for genetic analysis. Results: Proteinuria was detected in 175 genetically proven patients (72.6%), and the median age for developing proteinuria was 7.0 years. Fifty-two of 336 patients developed end-stage renal disease with a median renal survival age of 65.0 years. No obvious genotype–phenotype correlation was observed. Additionally, targeted sequencing for podocyte-related genes in patients with severe phenotypes revealed no obvious variants considered to be modifier genes except for 1 patient with a COL4A3 gene variant. Discussion: This study revealed that phenotypes in female XLAS patients may be severe, but genotype does not help to predict the disease severity. Clinicians must therefore pay careful attention to the clinical course and appropriate treatment in females with XLAS.

Keywords